期刊文献+

中药红藤方对大鼠的异位子宫内膜芳香化酶表达的影响 被引量:15

Effect of "Caulis Sargentodoxae Formula" on Aromatase Expression in Endometrial Rats
下载PDF
导出
摘要 目的:探讨中药红藤方对异位子宫内膜的抑制作用。方法:用手术自体移植法成功建立的子宫内膜异位症大鼠模型,随机分成5组:红藤方高剂量组(80g生药/kg,A组)、低剂量组(20g生药/kg,B组)、达那唑组(60mg/kg,C组)、去势组(D组)和模型组(E组),连续给药21d后,检测各组的血清E2水平及异位内膜和卵巢的芳香化酶的变化;另测定异位内膜的体积。结果:A组、C组和D组的异位内膜生长均明显受到抑制,且3组间无统计学差异(P>0.05),与E组比有统计学差异(P<0.05);组织学观察可见,异位内膜呈退化趋势,A、C和D组间大鼠血清中的E2水平无统计学差异(P>0.05),与E组相比有统计学差异(P<0.05);A组、C组及D组异位内膜、卵巢组织的芳香化酶P450低表达,A组与E组间有统计学差异(P<0.05)。结论:红藤方可通过抑制异位内膜、卵巢的芳香化酶活性表达,降低局部雌激素含量,抑制异位内膜的生长,使异位内膜萎缩。 Objective: To explore the inhibit effect of "Caulis Sargentodoxae Formula" on the ectopic endometrium. Methods: The model of endometriosis was established by Autotransplantion, the animals were divided randomly into 5 groups: "Caulis Sargentodoxae Formula " high dose group (80 g/kg, Group A), low dose group (20 g/kg, Group B) and danazol group (60 mg/kg, group C), castrate dose group (group D), control group (group E). After continuous treatment for 21 d, the level of E2, aromatase in ectopic endometrium and ovary were detected for each group, the volume of the ectopic endometrium was also measured. Results: The growth of endometrium was obviously inhibited in group A, C and D. The inhibitory rates were not significantly different between these groups (P〉0.05), but were significantly different compared with group E (P〈0.05). Observation from the morphology features showed that implanted endometrial become degenerating. The level of E2 was not significantly different between group A, C and group D, but were significantly different compared with group E (P〈0.05). And also there was a significantly decrease in the expression of aromatase of ectopic endometrium and ovary in group A, C and D (P〉0.05), however, there was a significant difference between group A and group E (P〈0.05). Conclusion: "Caulis Sargentodoxae Formula" can hold-back the expression of aromatase in ectopic endometrium and ovary so as to decrease the level of E2, it can inhibit the growth of the ectopic endometrium.
出处 《生殖与避孕》 CAS CSCD 北大核心 2008年第7期385-390,423,共7页 Reproduction and Contraception
基金 上海市教委第五期重点学科中医妇科项目,项目号:j50306
关键词 中药红藤方 子宫内膜异位症 芳香化酶 Caulis Sargentodoxae Formula endometriosis aromatase
  • 相关文献

参考文献11

  • 1Bulun SE, Fang Z, Imir G, et al. Aromatase and endometriosis. Sem in Reprod Med, 2004, 22(1):45-50.
  • 2杨峰,李凤梅,束兰娣(指导),张婷婷(指导).红藤方治疗子宫内膜异位症82例临床观察[J].山东中医杂志,2006,25(12):824-825. 被引量:24
  • 3丁玲,王金桃,周芩,马晓晨,程玉英,闫建文.雌激素孕激素与宫颈癌关系的病例对照研究[J].山西医药杂志,2006,35(2):95-97. 被引量:4
  • 4Fazleabas AT, Brudney A, Chai D, et al. Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil Steril, 2003, 80(Suppl 2):820-7.
  • 5Wang Z, Yoshida S, Negoro K, et al. Polymorphisms in the estrogen receptor beta gene but not estrogen receptor alpha gene affect the risk of developing endometriosis in a Japanese population, Fertil Steril, 2004, 81(6):1 650-6.
  • 6Asghar T, Yoshida S, Kennedy S, et al, The tumor necrosis factor-{alpha} promoter-1031C polymorphism is associated with decreased risk of endometriosis in a Japanese population. Hum Reprod, 2004, 19(11):2 509-14.
  • 7Kharfi A, Labelle Y, Mailloux J, et aL Deficient expression of tumor necrosis factor receptor type 2 in the endometrium of women with endometriosis, Am J Reprod Immunol, 2003, 50(1):33-40.
  • 8束兰娣.红藤方对子宫内膜异位症纤溶酶原的影响[J].中国现代临床医药杂志,2001,2(2):46-47.
  • 9张婷婷,刘津翚,束兰娣,戴德英,朱焰,邱晓燕,孙祖越,曹霖.红藤方对子宫内膜异位症大鼠MMP-9和MMP-2蛋白表达的干预作用[J].上海中医药大学学报,2005,19(4):48-51. 被引量:22
  • 10张婷婷,陈麒,朱抗美,曹霖,何桂林,孙祖越,束兰娣,戴德英.中药“红藤方”对子宫内膜异位症模型大鼠异位内膜的形态学影响[J].生殖与避孕,2005,25(12):716-719. 被引量:13

二级参考文献36

  • 1朱亮 林丹丽 等.红藤水溶性提取物对血小板聚集、冠脉流量、血栓形成和cAMP含量的影响[J].上海第一医学院学报,1986,13(5):346-350.
  • 2Franco EL,Schlecht NF,Saslow D.The epidemiology of cervical cancer.Cancer,2003,9(5):348-359.
  • 3Chim SJ,Basu PS,Jensen A.Cervicalcancer:etiology,pathogensis,treament,and future vaccines.Asian Pac J Cancer Prev,2002,3(3):207-214.
  • 4Moreno V,Bosch FX,Munoz N,et al.Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection:the IARC multicentric case-control study.Lancet,2002,359:1085-1092.
  • 5Bosch FX,Lorincz A,Munoz N,et al.The causal relation between human papillomavirus and cervical cancer.J Clin Pathol,2002,55:244-265.
  • 6Green G,Gonzalez A,Smith JS,et al.Human papillomavirus infection and use of oral contraceptives.Br J Cancer,2003,88:1713-1720.
  • 7Shapiro S,Rosenberg L,Hoffman M,et al.Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa).Cancer Causes Control,2003,14(5):485-495.
  • 8Villiers EM.Relationship between steroid hormone contraceptives and HPV,cervical intraepithelial neoplasia and cervical carcinoma.Int J Cancer,2003,103(6):705-708.
  • 9Moodley M,Moodley J,Chetty R,et al.The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer:a review.Int J Gynecol Cancer,2003,13(2):103-110.
  • 10Lubianca JN,Gordon CM & Lauter MR."Add-back" therapy for endormetriosis in adolescsnts.J Repord Med,1998,43(3):164-72.

共引文献54

同被引文献231

引证文献15

二级引证文献129

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部